Salen G, Shefer S, Tint G S, Nicolau G, Dayal B, Batta A K
J Clin Invest. 1985 Aug;76(2):744-51. doi: 10.1172/JCI112030.
To examine the defect in side-chain oxidation during the formation of bile acids in cerebrotendinous xanthomatosis, we measured in vitro hepatic microsomal hydroxylations at C-12 and C-25 and mitochondrial hydroxylation at C-26 and related them to the pool size and synthesis rates of cholic acid and chenodeoxycholic acid as determined by the isotope dilution technique. Hepatic microsomes and mitochondria were prepared from seven subjects with cerebrotendinous xanthomatosis and five controls. Primary bile acid synthesis was markedly reduced in cerebrotendinous xanthomatosis as follows: cholic acid, 133 +/- 30 vs. 260 +/- 60 mg/d in controls; and chenodeoxycholic acid, 22 +/- 10 vs. 150 +/- 30 mg/d in controls. As postulated for chenodeoxycholic acid synthesis, mitochondrial 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha-diol was present in all specimens and was 30-fold more active than the corresponding microsomal 25-hydroxylation. However, mean mitochondrial 26-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha-diol was less active in cerebrotendinous xanthomatosis than in controls: 59 +/- 17 compared with 126 +/- 21 pmol/mg protein per min. As for cholic acid synthesis, microsomal 25-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol was substantially higher in cerebrotendinous xanthomatosis and control preparations (620 +/- 103 and 515 +/- 64 pmol/mg protein per min, respectively) than the corresponding control mitochondrial 26-hydroxylation of the same substrate (165 +/- 25 pmol/mg protein per min). Moreover in cerebrotendinous xanthomatosis, mitochondrial 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol-26-hydroxylase activity was one-seventh as great as in controls. Hepatic microsomal 12 alpha-hydroxylation, which may be rate-controlling for the cholic acid pathway, was three times more active in cerebrotendinous xanthomatosis than in controls: 1,600 vs. 500 pmol/mg protein per min. These results demonstrate severely depressed primary bile acid synthesis in cerebrotendinous xanthomatosis with a reduction in chenodeoxycholic acid formation and pool size disproportionately greater than that for cholic acid. The deficiency of chenodeoxycholic acid can be accounted for by hyperactive microsomal 12 alpha-hydroxylation that diverts precursors into the cholic acid pathway combined with decreased side-chain oxidation (mitochondrial 26-hydroxylation). However, side-chain oxidation in cholic acid biosynthesis may be initiated via microsomal 25-hydroxylation of 5beta-cholestane-3alpha,7alpha,12alpha-triol was substantially lower in control and cerebrotendinous xanthomatosis liver. Thus, separate mechanisms may exist for the cleavage of the cholesterol side chain in cholic acid and chenodeoxycholic acid biosynthesis.
为研究脑腱黄瘤病中胆汁酸形成过程中侧链氧化的缺陷,我们测定了体外肝脏微粒体在C-12位和C-25位的羟化作用以及线粒体在C-26位的羟化作用,并将其与通过同位素稀释技术测定的胆酸和鹅去氧胆酸的库容量及合成速率相关联。从7例脑腱黄瘤病患者和5例对照者中制备肝脏微粒体和线粒体。脑腱黄瘤病中初级胆汁酸合成显著减少,如下所示:胆酸,对照者为260±60mg/d,脑腱黄瘤病患者为133±30mg/d;鹅去氧胆酸,对照者为150±30mg/d,脑腱黄瘤病患者为22±10mg/d。正如对鹅去氧胆酸合成所推测的那样,所有标本中均存在5β-胆甾烷-3α,7α-二醇的线粒体26-羟化作用,且其活性比相应的微粒体25-羟化作用高30倍。然而,脑腱黄瘤病患者中5β-胆甾烷-3α,7α-二醇的平均线粒体26-羟化作用比对照者低:分别为59±17与126±21pmol/mg蛋白每分钟。至于胆酸合成,5β-胆甾烷-3α,7α,12α-三醇的微粒体25-羟化作用在脑腱黄瘤病患者和对照者的制剂中(分别为620±103和515±64pmol/mg蛋白每分钟)显著高于相同底物相应的对照线粒体26-羟化作用(165±25pmol/mg蛋白每分钟)。此外,在脑腱黄瘤病中,线粒体5β-胆甾烷-3α,7α,12α-三醇-26-羟化酶活性仅为对照者的七分之一。肝脏微粒体12α-羟化作用可能是胆酸途径的速率控制步骤,在脑腱黄瘤病患者中其活性比对照者高3倍:分别为1600与500pmol/mg蛋白每分钟。这些结果表明脑腱黄瘤病中初级胆汁酸合成严重受损,鹅去氧胆酸形成减少且库容量降低,其程度比胆酸不成比例地更大。鹅去氧胆酸的缺乏可归因于微粒体12α-羟化作用亢进,其将前体物质转移至胆酸途径,同时伴有侧链氧化(线粒体26-羟化作用)减少。然而,胆酸生物合成中的侧链氧化可能通过5β-胆甾烷-3α,7α,12α-三醇的微粒体25-羟化作用起始,而在对照者和脑腱黄瘤病患者肝脏中该作用显著降低。因此,胆酸和鹅去氧胆酸生物合成中胆固醇侧链的裂解可能存在不同机制。